VIENNA, Va., March 14 /PRNewswire-FirstCall/ -- CEL-SCI Corporation announces that its Chief Executive Officer, Geert Kersten, is a featured presenter at the Biotech/Pharma/Healthcare On-line Forum. The webcast presentation is scheduled for Thursday, March 15, 2007 at 10:30 a.m. (Eastern Daylight Time) and can be accessed via the Internet at http://www.informedinvestors.com.
The Company's lead product, Multikine(R), has FDA go-ahead to start a global Phase III clinical trial in advanced primary head and neck cancer patients. In a Phase II clinical trial, Multikine was shown to increase overall survival by 33% 42 months after surgery.
Company Contact: Gavin de Windt CEL-SCI Corporation (703) 506-9460
CEL-SCI CorporationCONTACT: Gavin de Windt, +1-703-506-9460, of CEL-SCI Corporation
